Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Case report

A HELLP syndrome complicates a gestational trophoblastic neoplasia in a perimenopausal woman: a case report

Authors: Guillaume Vogin, François Golfier, Touria Hajri, Agnès Leroux, Béatrice Weber

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

HELLP syndrome is a combination of symptoms described as hemolysis, elevated liver enzymes and low platelets, that complicates 0.01–0.6 % of pregnancies. HELLP syndrome has been scarcely reported associated with partial moles, another rare complication of pregnancy. This manuscript describes the only reported case of HELLP syndrome associated with a complete invasive hydatiform mole.

Case presentation

We report a perimenopausal patient in prolonged remission from an uncommon high-risk invasive complete mole. The diagnosis was set in a context of early onset preeclampsia and HELLP syndrome. The development of life-threatening complications required primary hysterectomy. Postoperative hCG quickly returned to normal with EMA/CO multi-agent chemotherapy.

Conclusion

Our patient is in prolonged remission from a complete mole complicated with EOP and HELLP syndrome. This exceptional case of complicated gestational trophoblastic neoplasia reflects a very rare condition in which several risk factors for placental ischemia are associated. Emergency hysterectomy should be considered as salvage initial treatment in such life-threatening situations.
Literature
1.
Joshi D, James A, Quaglia A, Westbrook RH, Heneghan MA. Liver disease in pregnancy. Lancet. 2010;375(9714):594–605.CrossRefPubMed
2.
Berkowitz GS, Skovron ML, Lapinski RH, Berkowitz RL. Delayed childbearing and the outcome of pregnancy. N Engl J Med. 1990;322(10):659–64.CrossRefPubMed
3.
Savage PM, Sita-Lumsden A, Dickson S, Iyer R, Everard J, Coleman R, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstet Gynaecol. 2013;33(4):406–11.CrossRefPubMed
4.
Tsuji K, Yagi S, Nakano R. Increased risk of malignant transformation of hydatidiform moles in older gravidas: a cytogenetic study. Obstet Gynecol. 1981;58(3):351–5.PubMed
5.
Elias KM, Goldstein DP, Berkowitz RS. Complete hydatidiform mole in women older than age 50. J Reprod Med. 2010;55(5–6):208–12.PubMed
6.
Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. Gynecol Oncol. 2009;112(3):654–62.CrossRefPubMed
7.
Hammond CB, Weed Jr JC, Currie JL. The role of operation in the current therapy of gestational trophoblastic disease. Am J Obstet Gynecol. 1980;136(7):844–58.CrossRefPubMed
8.
FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynaecol Obstet. 2002;77(3):285–7.CrossRef
9.
Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L, Dent J. Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979–1984). Br J Obstet Gynaecol. 1986;93(1):63–9.CrossRefPubMed
10.
Golfier F, Raudrant D, Frappart L, Mathian B, Guastalla JP, Trillet-Lenoir V, et al. First epidemiological data from the French Trophoblastic Disease Reference Center. Am J Obstet Gynecol. 2007;196(2):172.e1–5.CrossRef
11.
Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol. 1997;15(7):2636–43.PubMed
12.
Cole LA, Sasaki Y, Muller CY. Normal production of human chorionic gonadotropin in menopause. N Engl J Med. 2007;356(11):1184–6.CrossRefPubMed
13.
Mangili G, Giorgione V, Gentile C, Bergamini A, Pella F, Almirante G, et al. Hydatidiform mole: age-related clinical presentation and high rate of severe complications in older women. Acta Obstet Gynecol Scand. 2014;93(5):503–7.CrossRefPubMed
14.
15.
MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol. 2001;97(4):533–8.PubMed
16.
Varkonyi T, Nagy B, Fule T, Tarca AL, Karaszi K, Schonleber J, et al. Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similar. Placenta. 2011;32(Suppl):S21–9.CrossRefPubMed
17.
Falkert A, Yildiz A, Seelbach-Goebel B. Partial mole with fetal triploidy as a cause for imminent HELLP-syndrome at 16 weeks of gestation. Arch Gynecol Obstet. 2009;279(3):423–5.CrossRefPubMed
18.
Sherer DM, Dalloul M, Stimphil R, Hellmann M, Khoury-Collado F, Osho J, et al. Acute onset of severe hemolysis, elevated liver enzymes, and low platelet count syndrome in a patient with a partial hydatidiform mole at 17 weeks gestation. Am J Perinatol. 2006;23(3):163–6.CrossRefPubMed
19.
Stefos T, Plachouras N, Mari G, Cosmi E, Lolis D. A case of partial mole and atypical type I triploidy associated with severe HELLP syndrome at 18 weeks’ gestation. Ultrasound Obstet Gynecol. 2002;20(4):403–4.CrossRefPubMed
Metadata
Title
A HELLP syndrome complicates a gestational trophoblastic neoplasia in a perimenopausal woman: a case report
Authors
Guillaume Vogin
François Golfier
Touria Hajri
Agnès Leroux
Béatrice Weber
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2641-2

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes

Research article

Characterisation of the DNA sequence specificity, cellular toxicity and cross-linking properties of novel bispyridine-based dinuclear platinum complexes

Research article

Predicting general and cancer-related distress in women with newly diagnosed breast cancer

Study protocol

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study

Research article

Distribution and features of hematological malignancies in Eastern Morocco: a retrospective multicenter study over 5 years

Case report

A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits